Live
Clinical OMICsGLP-1 Drugs Reduce Crime-Linked BehaviorClinical OMICsMacrophage EGFR Activity Linked to Immune Suppression, Tumor Growth in Colorectal CancerClinical OMICsUnexpected Role for RNA Editing in Cancer Immune Evasion UncoveredClinical OMICsProactive Surveillance Pays Off for Patients with Li-Fraumeni SyndromeClinical OMICsCAR T Success Hinges on Microenvironment Response in GBMEndpoints NewsFDA warns telehealth companies over compounded GLP-1sBioPharma DiveUniQure to file gene therapy for approval, reflecting major shifts at FDABioWorldEdgewise heads to phase III with solid EDG-7500 data in HCMEndpoints NewsUK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy saysEndpoints NewsHackers claim they stole Novo Nordisk AI models, manufacturing recipesEndpoints NewsIn second reversal, FDA gives uniQure a green light to seek accelerated approvalBioPharma DiveJazz zeroes in on next-gen T cell engagers with AbCellera deal
Lonza News Jan 28, 2026

Lonza still intends to sell its capsules and health ingredients business - Endpoints News

Lonza still intends to sell its capsules and health ingredients business - Endpoints News

Body unavailable. Use the original source.